Laurent Audoly, Parthenon CEO

Can new drugs punch holes in can­cer's pro­tec­tive bar­ri­er? For Parthenon Ther­a­peu­tics, that's the $65M ques­tion

Imag­ine tak­ing an ice pick to the pro­tec­tive bar­ri­er that sur­rounds can­cer cells. That’s es­sen­tial­ly what Parthenon Ther­a­peu­tics is try­ing to do — and now a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.